Roche inks $308.6M collaboration deal with Lead Pharma, focusing on immune-mediated disease
Roche is wading deeper into the field of immune-mediated disease with a €260 million ($308.6 million) collaboration deal with Netherlands-based biotech Lead Pharma.
The giant pharma is putting down €10 million ($11.8 million) upfront to work with Lead over the next few years on researching a small molecule candidate that inhibits portions of the T helper 17 (TH17) cell pathway, which could treat a variety of autoimmune diseases. Once a preclinical candidate is chosen, it’ll be up to Roche to develop and commercialize it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.